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Abstract
Background At the dermatology service of the General Hospital of Mexico City, Mexico, two patients, father and son,
with black-grain mycetoma were seen. The grains were isolated, and the cultured fungi were identified as Madurella
mycetomatis based on morphology. Using the M. mycetomatis specific PCR, amplicons of a different size than that of
theM. mycetomatis type strain were obtained.
Objective To determine the causative agent of the two black-grain mycetoma cases and develop non-culture-based
diagnostic tools to identify them to the species level.
Methods The M. mycetomatis specific, the internal transcribed spacer (ITS) region, b-tubulin (BT) and ribosomal bind-
ing protein 2 (RBP2) PCRs were used to confirm the identity of the isolates. Genetic variation was established by amplifi-
cation fragment length polymorphisms. To determine the antifungal susceptibility profile, the SensititreTM YeastOneTM
assay was used. To develop a species-specific PCR primers were designed on the sequenced PCR amplicon from the
M. mycetomatis specific PCR.
Results By analyzing the ITS, BT and RBP2 regions the isolates were identified as Madurella pseudomycetomatis. The
isolates from father and son were similar but not identical to M. pseudomycetomatis from Venezuela and one from an
unknown origin. Madurella pseudomycetomatis isolates were inhibited by itraconazole, posaconazole and voriconazole
but showed increased MIC values for amphotericin B and fluconazole. They were not inhibited by the echinocandins and
five flucytosine. The two patients were treated with itraconazole resulting in cure for the father while the son was lost to
follow-up. The species-specific PCR developed forM. pseudomyceotmatis was discriminative and specific.
Conclusion Madurella pseudomycetomatis is genetically diverse with same susceptibility profile as M. mycetomatis
and causes eumycetoma in Latin America. The M. pseudomycetomatis specific PCR can be used to identify this causa-
tive agent to the species level; however, this needs to be validated in an endemic setting.
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Introduction
Mycetoma is chronic, granulomatous subcutaneous infection
characterized by inflammation, painless tumour-like lesions and
multiple sinuses discharging grains.1,2 It is endemic in tropical
and subtropical countries and can be caused by either bacteria
(actinomycetoma) or fungi (eumycetoma). In Mexico,
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actinomycetoma predominates over eumycetoma but in semi-
arid climate zones of Africa (Sudan, Senegal, Somalia) and
India.3–9 eumycetoma is more common. Madurella mycetoma-
tisis the main causative agent globally,10 while Nigrograna mack-
innonii predominates in Latin America.6 In Mexico, particularly
M. mycetomatis has been reported.11
Recently, novel Madurella agents causing mycetoma have
been recognized, i.e. Madurella fahalii, Madurella tropicana and
Madurella pseudomycetomatis.12 Morphological identification of
Madurella species is difficult, and hence molecular techniques
are necessary for differentiation.13 Susceptibility to antifungal
drugs differs between species. For instance, M. fahalii is not
inhibited by itraconazole in vitro unlike the other Madurella spe-
cies.12 Accurate identification is thus required for optimal treat-
ment of patients. Currently, a species-specific PCR is available
for M. mycetomatis,14 but the remaining agents can only be
identified by sequencing the internal transcribed spacer (ITS)
regions.15
Due to the paradigm shift in mycology, distribution, preva-
lence and endemism of various Madurella species are unclear.
Here, we show the presence of black-grain mycetoma caused by
M. pseudomycetomatis in South America. Since this species was
undistinguishable from the other Madurella species by morphol-
ogy and culture methods, a novel diagnostic PCR was developed
for identification to the species level.
Case reports
Case 1 A male, 66-year-old patient weighing 65 kg, presented
with a localized dermatosis from the right pelvis to the foot. The
central part and metatarsal region of the right foot showed a
tumorous lesion, fibrotic with several sinuses from which some
purulent material was exuded (Fig. 1a). The patient complained
of pain to palpation and diambulation. He was a resident of
Tapachula, Chiapas (1102 km southeast of Mexico City) and
worked as a farmer. He reported multiple injuries during a time
period of 18 years. The presumptive clinical diagnosis was myce-
toma. To confirm the diagnosis, a direct examination (KOH) of
the fistula exudate was taken. Multiple large dark grains of fila-
mentous consistency were observed, and a dark filamentous col-
ony with brown-ocher pigment was isolated Sabouraud-dextrose
agar media. Multiple brown hyphae with clamydoconidia were
observed after direct examination of the cultures, which is sug-
gestive for Madurella spp. On radiography, a little osteolytic
activity was demonstrated in the metatarsal bones (Fig. 1b). To
confirm the diagnosis, haematoxylin and eosin (H&E) staining
was performed on part of the biopsy material. This demon-
strated hyperkeratosis, irregular acanthosis and pseudoepithe-
liomatous hyperplasia. In the deep dermis and subcutaneous
tissue, a suppurative granulomatous process was observed, com-
posed of a lympho-histiocytic infiltrate, forming some microab-
scesses with the presence of multiple dark grains formed by
thick, septate hyphae (Fig. 1c). The patient reported receiving
multiple previous treatments based on sulphamethoxazole-
trimethoprim, ketoconazole, as well as multiple unspecified
topical treatments. The patient was treated with itraconazole
400 mg/day for 18 months; the dose was subsequently lowered
to 300 mg/day for 6 months, achieving clinical and mycological
cure after 2 years of treatment.
Case 2 A 28-year-old male, equally 65 kg, presented with a
localized dermatosis from the left pelvis to the foot, affecting
the first metatarsal and the cuboid zone to the malleolus. The
lesion started two years ago as a small lesion. The patient
itself referred to it as a ‘pimple’. The small lesion grew slowly
to a tumoral lesion with multiple sinuses from which some
purulent material drained upon pressure (Fig. 1d). The
patient complained of pain to palpation and itching. He was
resident of Comaltitlan, Chiapas (1041 km southeast of Mex-
ico City) and son of the patient 1. Like his father, he was a
farmer. He reported multiple injuries due to his occupation,
and in particular referred to a trauma with spines. He
received multiple treatments with unspecified antibiotics as
well as homemade herb-based treatments, without obtaining
any response. To identify the causative agent direct examina-
tion (KOH) of the exudate of the lesion was performed. Mul-
tiple black grains of filamentary consistency were observed. A
black colony with ocher pigment was obtained on Sabouraud
dextrose agar media consisting of multiple thick septate
hyphae with clamydodoconidia, suggestive of Madurella spp.
On radiography, discrete osteolytic activity was demonstrated
(Fig. 1e). A biopsy with H & E staining showed hyperkerato-
sis, irregular acanthosis and pseudoepitheliomatous hyperpla-
sia. A suppurative granuloma formed by an infiltrate with
lymphocytes and histiocytes, with some microabscesses and
the presence of grains formed by thick and dark hyphae was
observed in the deep dermis and subcutaneous tissue
(Fig. 1f). The final clinical diagnosis was eumycetoma with
black grains. The treatment was itraconazole at a dose of
400 mg/day for one year, reaching clinical and mycological
cure but patiently was subsequently lost to follow-up
Materials and methods
Strains and growth conditions
Grains were isolated from the biopsies of the patients (Mex2a
and Mex3a) above and cultured on Sabouraud’s dextrose agar
(SDA) at 37 °C for two weeks. Phenotypic and morphological
identification was performed at the Dermatology Service of the
General Hospital Mexico City, Mexico. Additional fungal strains
used in the study were grown and identified in a similar way:
VE1, CBS102791, CBS129177T, CBS216.29, CBS248.48,
UMIP81.77, UMIP582.60, UMIP1137.76, MM55, P1, CBS
102793, CBS 201.38T, CBS 132272 and CBS 128765.
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DNA extraction
DNA from Fungal isolates was extracted as described else-
where.16 Using the ZR Fungal/Bacterial DNA MiniPrepTM kit
(Zymo Research, Irvine, CA, USA) or NucleoMag plant kit
extraction (Macherey-Nagel, Dueren, Germany) in a King-
FisherTM Flex system (Thermo Fisher Scientific, Basingstoke,
Hants, UK).
Madurella mycetomatis specific PCR
Madurella mycetomatis specific PCR was performed as previ-
ously described.14 Briefly, the PCR was performed in 25 µL reac-
tion volume containing 0.2 U of Supertaq DNA polymerase
(Eurogentec Seraing, Liege, Belgium), Supertaq buffer,
10 mmol/L dNTP mix (Thermo fisher), 50 pmol of each primer
(Table 1) and 2.5 of DNA (40 ng/µL). Forty cycles amplification
Figure 1 (a) Clinical presentation of case 1 with eumycetoma of the right foot with deformities and multiple sinuses. (b) Case 1 X-ray
images showing osteolytic activity in the metatarsals. (c) H and E stained with characteristic grain section surrounded by cementious
material (940). (d) Clinical presentation of Case 2 with eumycetoma of the right limb. (e) Case 2 X-ray images showing discrete osteolytic
activity. (f) Histological section showing grains composed of hyphal material and surrounded by cementious material (940).
Table 1 Primers used for molecular identification of isolates14,15,32
Primer Function Sequence
V9G ITS PCR/sequencing 50-TTACGTCCCTGCCCTTTGTA-30
LS266 ITS PCR/sequencing 50-GCATTCCCAAACAACTCGACTC-30
b-tubulinFw b-Tubulin PCR/sequencing 50-TTCCGTCCCGACAACTTCGT-30
b-tubulin Rv b-Tubulin PCR/sequencing 50-CTCAGCCTCAGTGAACTCCAT-30
b-tubulin Fw2 b-Tubulin sequencing 50-TGACCCAGCAGATGTTCGAC-30
RBP2 RBP2 PCR/sequencing 50-GAYGAYMGWGATCAYTTYGG-30
RBP2 RBP2 PCR/sequencing 50-GAATRTTGGCCATGGTRTCCAT-30
26.1a M. mycetomatis specific PCR 50-AATGAGTTGGGCTTTAACGG-30
26.1b M. mycetomatis specific PCR 50-GCAACACGCCCTGGGCGA-30
28.3a M. mycetomatis specific PCR 50-TCCCGGTAGTGTAGTGTCCCT-30
28.3b M. mycetomatis specific PCR 50-TCCGCGGGGCGTCCGCCGGA-30
MP1 M. pseudomycetomatis specific PCR 50-GCGTGAAGAGTCTGCTGTTG-30
MP2 M. pseudomycetomatis specific PCR 50-TAGCCTGAATCCCACAAACC-30
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was performed using the T100 Thermocycler (Biorad, Veenen-
daal, The Netherlands) with the following conditions: 94 °C for
4 min, 94 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s and a final
extension at 72 °C for 7 min. Two M. mycetomatis isolates were
included as positive controls (MM55 and P1) and isolates of
M. fahalii (CBS 102793) and M. tropicana (CBS 201.38T) were
included to evaluate cross-reaction.
Multilocus sequencing
Amplification and sequencing of rDNA ITS, b-tubulin (BT) and
Ribosomal Binding Protein 2 (RBP2) genes amplification and
sequencing were performed as described elsewhere15,17 using the
BigDye Terminator v3.1 Ready Reaction Cycle Sequencing Kit
(Applied Biosystems, Waltham, MA, USA) according to the
manufacturer’s instructions. The sequences were analyzed using
Chromas software (Technelysium Pty Ltd, South Brisbane, Aus-
tralia) and obtained sequences were deposited in GenBank
(Mex2a ITS accession number: MN545597, Mex3a ITS accession
number: MN545598).
Amplification fragment length polymorphisms
Amplification fragment length polymorphisms (AFLP) analysis
was performed as described previously.18–20 Following amplifica-
tion, the AFLP fragments were ran by capillary electrophoresis.
The capillary electrophoresis 20 µL reaction consisted of a 2 µL
(1:10 dilution) of the AFLP product, 0.1 µL of Genescan 600LIZ
size marker (Thermo Fisher, Landsmeer, The Netherlands) and
17.9 µL HiDi Formamide (Thermo Fisher). Data were analyzed
using Bionumerics software (Applied Maths, Sint-Martens-
Latem, Belgium).
Antifungal susceptibility profile
Minimum inhibitory concentrations (MICs) were determined
using the SensititreTM YeastOneTM Alamar Blue assay (Thermo
Fisher Scientific) as previously described.21 Briefly, isolates were
grown in RPMI 1640 medium (Lonza, Verviers, Belgium) sup-
plemented with L-glutamine (0.3 g/L) and 20 mmol/L morpho-
linepropanesulphonic acid (MOPS) for 7 days and the mycelia
were harvested by 5 min centrifugation (Rotanta 46R, Tuttlin-
gen, Germany) at 2158 g and washed with RMPI. The inoculum
was homogenized, by sonicating the mycelia for 10 s at 28 lm
(Soniprep, Healthfield, East Sussex, UK). A fungal suspension
was made in YeastOne Broth (Thermo ScientificTM, Santa Fe,
NM, USA) with a transmission range between 68–72% (Novas-
pec II, Pharmacia Biotech, Uppsala, Sweden). One hundred
microlitre of the fungal suspension was used to rehydrate the
YO10 Sensititre YeastONE plate and incubated for 7 days at
37 °C. The YO10 panel contained serial two-fold dilutions of
anidulafungin (0.015–8 lg/mL), micafungin (0.008–8 lg/mL),
caspofungin (0.008–8 lg/mL), 5-flucytosine (0.06–64 lg/mL),
amphotericin B (0.12–8 lg/mL), posaconazole (0.008–8 lg/
mL), voriconazole (0.008–8 lg/mL), itraconazole (0.015–16 lg/
mL) and fluconazole (0.12–256 lg/mL). The MICs of this slow-
growing filamentous fungus were read at day 7 following incuba-
tion at 37 °C.
Madurella pseudomycetomatis specific PCR
The sequence obtained (Accession number: MN384980) from
M. mycetomatis specific PCR of M. pseudomycetomatis was used
to design primers for a species-specific PCR for M. pseudomyce-
tomatis (see Table 1). The PCR consisted of 12.5 µL of Fastart
Master mix (Roche diagnostics, Almere, The Netherlands),
0.5 µm of forward primer and reverse primer, 8 µL H2O and
add 40 ng of genomic DNA in a 25 µL reaction volume. The
PCR conditions were as follows: 4 min 94 °C, 30 s at 94 °C,
30 s at 55 °C and 1 min at 72 °C (35 cycles) followed by final
extension time of 4 min at 72 °C. The PCR products were visu-
alized on 1% agarose gel electrophoresis.
Results
The initial diagnosis of both patients was mycetoma caused by
M. mycetomatis, which was based on the hairy aspect of the
colonies isolated from the grains. Microscopically dark hyphae
with chlamydospores and absence of conidia were noted. For
verification, the isolates were tested using currently applied
M. mycetomatis specific PCRs.14 With primer pair 26.1b and
28.3b, a 370 bp amplicon was obtained for both Mexican iso-
lates as well as for the two M. mycetomatis control isolates
(Fig. 2a). When primer pair 26.1a and 28.3a was used, a 640 bp
amplicon was obtained, which was 150 bp larger than the
expected 490 bp amplicon obtained with the two M. mycetoma-
tis control isolates (Fig. 2b, Lanes 1–2). The 640 bp amplicon
(GenBank: MN384980) had no homology to any known
sequence. Partial ITS, BT and RBP2 genes were sequenced for
identification. Upon BLAST analysis, the ITS sequences of iso-
lates Mex2a and Mex3a were found to be 100% identical to the
ITS sequence of M. pseudomycetomatis (JX280868.1). The RBP2
and BT sequences were 100% identical to the RBP2
(JN573211.1) and BT (JN573199.1) sequences of M. pseu-
domycetomatis strain. We, therefore, concluded that both Mex2a
and Mex3a are M. pseudomycetomatis isolates and that the cur-
rently used specific PCR for M. mycetomatis gave an amplicon
with M. pseudomycetomatis.
We evaluated if M. mycetomatis specific PCR also cross-re-
acted with other Madurella species. Amplicons of 370 bp were
obtained from all Madurella species other than M. pseudomyce-
tomatis using primer pair 26.1b and 28.3b. This result was con-
firmed by in silico analysis of the deposited ITS sequences. With
primer pair 26.1a and 28.3a, no amplification was obtained for
M. tropicana or M. fahalii (Fig. 2b).
The sequence of the 640 bp amplicon of M. pseudomyce-
tomatis was then used to develop a species-specific PCR
which generated a 325 bp amplicon (Fig. 2c). Specificity was
tested using the primers in M. mycetomatis, M. fahalii and
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M. tropicana as well as in other agents of eumycetoma such
as Medicopsis romeroi and Falciformispora senegalensis. Ampli-
fication was obtained only in M. pseudomycetomatis which
confirmed the specificity of the PCR within this group of
tested species.
Since the isolates were obtained from father and son, we eval-
uated if these isolates could have been acquired from the same
environmental source. AFLP analysis revealed that the two iso-
lates were genetically similar but not identical. Furthermore,
they were similar but not identical to two isolates VE1 (from
Venezuela) and UMIP 1137.76 (unknown origin), respectively
(Fig. 3). They were, however, genetically distinct from the other
isolates obtained from other geographical regions. Moreover,
these Mexican isolates were phylogenetically distinct from
M. mycetomatis MM55 (CBS 131320) and M. fahalii
CBS102793.
Since M. fahalii is known to be less susceptible to itracona-
zolethan M. mycetomatis,12 we determined the in vitro suscepti-
bility of M. pseudomycetomatis isolates against nine commonly
used antifungal agents. Madurella pseudomycetomatis isolates
were susceptible to the azole class of antifungals (itraconazole,
posaconazole and voriconazole), and to amphotericin B as seen
in Table 2. The MIC50 for the antifungals were as follows: itra-
conazole (0.03 lg/mL), posaconazole (0.015 lg/mL), voricona-
zole (0.06 lg/mL) fluconazole (16 lg/mL) and amphotericin B
(0.5 lg/mL). The isolates were not inhibited by the echinocan-
dins and 5-flucytosine (MIC50 ≥8 lg/mL and ≥64 lg/mL,
respectively). Both patients were treated with itraconazole and
patient Mex2a had mycological and clinical cure after two
years, while patient Mex3a showed clinical improvement but
was lost for follow-up.
Discussion
The two cases of eumycetoma in father and son caused by
M. pseudomycetomatis were originally identified as M. myce-
tomatis by conventional techniques and using M. mycetomatis
specific primers 26.1b and 28.3b.14 The primers were developed
prior to the description of additional Madurella species,12,14 and
thus it is not surprising that these are not recognized. Only when
primers 26.1a and 28.3a correct identity of the etiologic agent
was revealed. However, in another study using the same
M. mycetomatis primers PCR, no cross-reactivity with M. Pseu-
domycetomatis was reported.22
Madurella mycetomatis, M. fahalii, M. tropicana and M. pseu-
domycetomatis are indistinguishable by culture.23 The few iso-
lates from South and Central America identified by molecular
techniques were found to be M. pseudomycetomatis instead of
M. mycetomatis.24 Therefore, it cannot be excluded that
M. pseudomycetomatis is the dominant Madurella species in
Latin-America,11 rather than M. mycetomatis. Our specific
molecular assay was able to discriminate M. pseudomycetomatis
from the other Madurella species with a high degree of
specificity. The ITS-based PCR respects intra-specific variability
as shown, for example in AFLP pattern. Since
Figure 2 (a)Madurella mycetomatis specific PCR (26.1b and 28.3b) cross reacts with otherMadurella species with identical bands.
Lanes 1–2:M. mycetomatis isolates, Lanes 3–9:Madurella pseudomycetomatis, lanes 10–12:M. fahalii,M. tropicana lanes 13-14:
M. tropicana and 15: Negative control, L: 100 bp plus ladder. (b) Primer pair 26.1a and 28.3a Lanes 1–2:M. mycetomatis, Lanes 3–10:
Madurella pseudomycetomatis, Lanes 11–13:M. fahalii Lanes 14–15:M. tropicana and 16: negative control. (c)Madurella pseudomyce-
tomatis specific PCR. Lanes 1–10:Madurella pseudomycetomatis, Lanes 11–12:M. mycetomatis, Lanes 13–14M. fahalii, Lanes: 15–16
M. tropicana and 17: negative control.
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M. pseudomycetomatis might cause a considerable portion of
eumycetoma cases in Latin-America, it is important to know the
antifungal susceptibility profile and the clinical response to anti-
fungal agents. Therefore, we evaluated the susceptibility of seven
M. pseudomycetomatis isolates to the commonly used antifungals
using the SensititreTM YeastOneTM system. Madurella pseudomyce-
tomatis isolates were susceptible in vitro to the azoles and
amphotericin B with the lowest MIC for posaconazole. However,
they were not inhibited by fluconazole. The echinocandins and
5-flucytosine did not also inhibit the growth of M. pseudomyce-
tomatis.25–28 This susceptibility pattern was similar to that
reported in a previous study22 and did not differ from that of
M. mycetomatis isolates.25,28,29 It is, therefore, to be expected
that eumycetoma caused by M. pseudomycetomatis maybe trea-
ted with similar antifungal agents as patients with eumycetoma
caused by M. mycetomatis. Indeed, the cases from father and son
were both treated with itraconazole and both showed clinical
improvement. The M. pseudomycetomatis case from Venezuela
was treated for 72 months with itraconazole and was also
cured.24 This is similar to the response rate for M. mycetomatis
in which 56.2%30 to 69%31 cases responded to azole treatment.
In conclusion, we here demonstrated that M. pseudomyce-
tomatis causes eumycetoma in Latin-America. We developed a
species-specific PCR which can be used to identify this causative
agent to the species level. Madurella pseudomycetomatis has an
antifungal susceptibility profile similar to that of M. mycetomatis
and medical treatment of M. pseudomycetomatis eumycetoma
can be similar to that recommended for M. mycetomatis
eumycetoma.
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